Found: 35
Select item for more details and to access through your institution.
Comparative Analysis of Morphological and Functional Effects of 225 Ac- and 177 Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 23, p. 16845, doi. 10.3390/ijms242316845
- By:
- Publication type:
- Article
Prostat Kanseri Hastalarinda F-18-RHPSMA-7.3 PET/BT'de Enjekte Edilen Ligand Miktari Biyodağılımı Etkiliyor mu?
- Published in:
- Nuclear Medicine Seminars, 2020, v. 6, p. 47
- By:
- Publication type:
- Article
Safety and Efficacy of [<sup>177</sup>Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 8, p. 1244, doi. 10.2967/jnumed.122.265259
- By:
- Publication type:
- Article
Prognostic Role of <sup>68</sup>Ga-PSMA11 PET–Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 6, p. 896, doi. 10.2967/jnumed.122.264962
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
<sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.262861
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
<sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 203, doi. 10.2967/jnumed.121.262861
- By:
- Publication type:
- Article
<sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 8, p. 203, doi. 10.2967/jnumed.121.262861
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
<sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.262861
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
<sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.262861
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
<sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.262861
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 3, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 1, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
The Influence of Specific Activity on the Biodistribution of <sup>18</sup>F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262475
- By:
- Publication type:
- Article
The Influence of Specific Activity on the Biodistribution of <sup>18</sup>F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262471
- By:
- Publication type:
- Article
BRIEF COMMUNICATION: The Influence of Specific Activity on the Biodistribution of <sup>18</sup>F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.262471
- By:
- Publication type:
- Article
Positive predictive value and correct detection rate of <sup>18</sup>F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.255661
- By:
- Publication type:
- Article
<sup>18</sup>F‐rhPSMA‐7 positron emission tomography for the detection of biochemical recurrence of prostate cancer following radical prostatectomy.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.119.234914
- By:
- Publication type:
- Article
Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of Novel Radiohybrid PSMA, <sup>18</sup>F- rhPSMA-7, in Patients with Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.119.234609
- By:
- Publication type:
- Article
<sup>177</sup>Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.118.223149
- By:
- Publication type:
- Article
<sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 11, p. 1579, doi. 10.2967/jnumed.118.223149
- By:
- Publication type:
- Article
Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, p. 13S, doi. 10.2967/jnumed.118.220566
- By:
- Publication type:
- Article
Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies.
- Published in:
- Journal of Nuclear Medicine, 2018, v. 59, n. 8, p. 1172, doi. 10.2967/jnumed.118.214379
- By:
- Publication type:
- Article
Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177 Lu-PSMA and Combined 225 Ac- and 177 Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation.
- Published in:
- Diagnostics (2075-4418), 2022, v. 12, n. 8, p. 1926, doi. 10.3390/diagnostics12081926
- By:
- Publication type:
- Article
Positronen-Emissions-Tomographie mit Computertomographie/Magnetresonanztomographie für das primäre Staging des Prostatakarzinoms.
- Published in:
- Der Radiologe, 2021, v. 61, n. 9, p. 818, doi. 10.1007/s00117-021-00895-3
- By:
- Publication type:
- Article
Whole-body uptake classification and prostate cancer staging in <sup>68</sup>Ga-PSMA-11 PET/CT using dual-tracer learning.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 2, p. 517, doi. 10.1007/s00259-021-05473-2
- By:
- Publication type:
- Article
A rare case of polyostotic fibrous dysplasia detected on <sup>18</sup>F-rhPSMA-7 PET/CT.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2020, v. 47, n. 12, p. 2927, doi. 10.1007/s00259-020-04751-9
- By:
- Publication type:
- Article
Safety of High-Dose Botulinum Toxin Injections for Parotid and Submandibular Gland Radioprotection.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy.
- Published in:
- EJNMMI Research, 2021, v. 11, n. 1, p. 1, doi. 10.1186/s13550-021-00818-2
- By:
- Publication type:
- Article
PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy.
- Published in:
- EJNMMI Research, 2021, v. 11, n. 1, p. 1, doi. 10.1186/s13550-021-00818-2
- By:
- Publication type:
- Article